Jonathan Wolleben’s rating is based on the significant potential he sees in Structure Therapeutics, Inc., particularly due to its position as a leader in small molecule amylin agonists.

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Dual Amylin and Calcitonin Receptor Agonist (DACRA ... Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment ...

VK2809 is an orally available small molecule agonist of the thyroid ... we announced data from a new program targeting novel agonists of the amylin receptor for the potential treatment of obesity.

VK2735 is a wholly owned dual agonist of the glucagon like peptide ... Like VK2809, VK0214 is also an orally available small molecule that is selective for the beta isoform of the thyroid hormone ...